Role and Expectations of Biosimilars in Psoriasis Treatment (Dialogue: Dr. Akiharu Morita, Nagoya City University)

The Japan Biosimilar Association (Chairman: Tatsuo Kurokawa) has released the 9th installment of its Chairman's Dialogue series on its official website. The theme is 'Role and Expectations of Biosimilars in Psoriasis Treatment.' Dr. Akiharu Morita, Professor of Aging and Environmental Dermatology at Nagoya City University Graduate School of Medicine, and Chairman Tatsuo Kurokawa discuss the current status and challenges of psoriasis treatment, as well as the positioning and future prospects of biosimilars.

Psoriasis is a chronic inflammatory disease, and treatment options have expanded significantly with the advent of biological products. Key points discussed include:
- An estimated 400,000 to 500,000 psoriasis patients in Japan.
- The advent of biologicals has made 'PASI 90/100 achievement' a realistic goal. Future focus is on 'bio-free' states and reducing patient burdens.
- Eliminating regional disparities in medical access is crucial.
- Patient-centric and sustainable treatment selection is essential.
- Biosimilars contribute to reduced patient burdens, healthcare cost optimization, and the sustainability of the national health insurance system.
- Switching from reference biological products should be conducted based on scientific evidence and in consultation with the attending physician.

This dialogue provides general information and is not intended to promote specific drugs or replace medical diagnosis or treatment.